vaccine 

16274
CET6GRETOEFLIELTS
单词释义
n.疫苗,菌苗
adj.牛痘的,预防疫苗的,种痘的
词根词缀记忆/谐音联想记忆 补充/纠错
词根vac(= vacant,空白的) + ci …………
其他怎么记补充/纠错
谐音记忆哇,可神 → 打了疫苗之后就不会得某种病,可神了 → 疫苗
 …………
词性拓展记忆 / 词形拓展记忆
原形:vaccine复数:vaccines
词组和短语补充/纠错
Bacillus Calmette-Guérin vaccine 卡介苗
homegrown vaccine 国产疫苗
injection of vaccine 注射疫苗
pandemic vaccine 大流行疫苗
smallpox vaccine 天花疫苗
problematic vaccine 问题疫苗
development and production of vaccine 疫苗的开发和生产
injection vaccine for Yellow Fever 黄热病注射疫苗
单词例句
We need these virus vaccine.
我们需要接种这些病毒疫苗。
Vaccines are the most effective against viruses.
疫苗对于病毒的防御是最有效果的。
As one of the world's leading mRNA vaccine developers, Moderna focuses on cancer immunotherapy, including mRNA-based medicine R&D and virus prevention technologies.
作为全球领先的mRNA疫苗开发商之一,莫德纳专注于癌症免疫疗法,包括基于mRNA的药物研发和病毒预防技术。
In the vaccine field, GSK will continue to showcase its blockbuster products, including a shingles vaccine, which showed 100 percent protective efficacy in Chinese adults aged 50 and above as shown in the latest research data, and a bivalent HPV vaccine, the only HPV vaccine using the AS04 innovative adjuvant system.
在疫苗领域,葛兰素史克将继续展示其重磅产品,包括带状疱疹疫苗,如最新研究数据所示,该疫苗对50岁及以上的中国成年人显示出100%的保护效力,以及二价HPV疫苗,该疫苗是唯一使用AS04创新佐剂系统的HPV疫苗。
For example, she said, the company's shingles vaccine was approved in China in May 2019 and was a key exhibit of the company during CIIE that year.
例如,她说,该公司的带状疱疹疫苗于2019年5月在中国获得批准,是该公司在当年CIIE期间的一个关键展品。
"Taking advantage of CIIE's spillover effect, we quickly completed commercial landing for the vaccine.
“利用CIIE的溢出效应,我们很快完成了疫苗的商业落地。
GSK has 23 other vaccine candidates in the development stage, including a respiratory syncytial virus (RSV) vaccine, which was approved by the United States Food and Drug Administration in May for the prevention of RSV infection in people aged 60 or older.
葛兰素史克还有23种其他候选疫苗处于开发阶段,其中包括一种呼吸道合胞病毒(RSV)疫苗,该疫苗于5月被美国食品和药物管理局批准用于预防60岁或以上人群感染RSV。
"We hope to bring this innovative vaccine to the Chinese market in the near future, which will be significant for the prevention and control of diseases in an aging society," she said.
她说:“我们希望在不久的将来将这种创新疫苗推向中国市场,这将对老龄化社会的疾病预防和控制具有重要意义。”。
Riding BRI, vaccine giant seeks more cooperation with overseas partnersChinese vaccine company Sinovac Biotech is in talks with potential partners to localize the production of its vaccines in more foreign countries, said its executives.
借助“一带一路”倡议,疫苗巨头寻求与海外合作伙伴开展更多合作。中国疫苗公司科兴生物技术有限公司高管表示,该公司正在与潜在合作伙伴进行谈判,以将其疫苗生产本地化到更多外国。
By localizing production through technology transfer and cooperation, Sinovac aims to achieve win-win results with foreign partners, including improving vaccine affordability and accessibility in host countries and spurring the development of the local vaccine and pharmaceutical sectors, the company said.
该公司表示,通过技术转让和合作实现生产本地化,科兴旨在与外国合作伙伴实现双赢,包括提高疫苗在东道国的可负担性和可及性,并促进当地疫苗和制药行业的发展。
The company's vaccine plans involving such technology transfer and localized production cooperation mainly include those for hepatitis A, polio, influenza and COVID-19.
该公司涉及此类技术转让和本地化生产合作的疫苗计划主要包括针对甲型肝炎、脊髓灰质炎、流感和新冠肺炎的疫苗计划。
During the post-pandemic era, many countries are still interested in obtaining COVID-19 vaccine production technology, in case of any future outbreaks, Yang said.
杨说,在后疫情时代,许多国家仍然有兴趣获得新冠肺炎疫苗生产技术,以防未来爆发疫情。
The pandemic taught us that vaccine production capacity is a matter of public safety and national security.
新冠疫情告诉我们,疫苗生产能力事关公共安全和国家安全。
We are welcomed by leaders of foreign countries to transfer technology and cooperate on localizing vaccine production," she added.
我们欢迎外国领导人在疫苗生产本地化方面进行技术转让和合作,”她补充道。
So far, Sinovac has entered into 17 technology licensing agreements for vaccine production in 12 countries, including seven countries participating in the BRI.
到目前为止,科兴已在12个国家签订了17项疫苗生产技术许可协议,其中包括7个参与“一带一路”倡议的国家。
Its flagship vaccine, the inactivated vaccine against COVID-19, has realized localized production in five countries involved in the initiative — Indonesia, Turkiye, Egypt, Malaysia and Algeria.
其旗舰疫苗新冠肺炎灭活疫苗已在印度尼西亚、土耳其、埃及、马来西亚和阿尔及利亚五个参与该倡议的国家实现了本地化生产。
In Turkiye, Sinovac and its local partner have built a formulation and packaging facility that will further enhance the country's vaccine production capacity.
在土耳其,科兴公司及其当地合作伙伴建立了一个配方和包装设施,这将进一步提高该国的疫苗生产能力。
Its advanced automated storage center in Egypt, which is currently the largest vaccine storage facility in Africa, will significantly boost Egypt's cold chain vaccine storage and distribution capabilities, consequently improving the vaccine supply chain across the continent.
其位于埃及的先进自动化储存中心目前是非洲最大的疫苗储存设施,将大大提高埃及的冷链疫苗储存和分销能力,从而改善整个非洲大陆的疫苗供应链。
According to the China Association for Vaccines, Chinese vaccine manufacturers have made substantial progress in strengthening their position in global vaccine value chains through transferring technologies, building overseas production sites, expanding cooperation on research and development and licensing out.
中国疫苗协会表示,中国疫苗制造商通过转让技术、建设海外生产基地、扩大研发合作和许可证发放,在加强其在全球疫苗价值链中的地位方面取得了实质性进展。
Yet, in seeking a greater global presence, Chinese vaccine makers must improve corporate governance, align with international standards, cultivate talent and build efficient cooperation networks with local partners, the report said.
然而,报告称,在寻求更大的全球影响力时,中国疫苗制造商必须改善公司治理,与国际标准保持一致,培养人才,并与当地合作伙伴建立高效的合作网络。
US mRNA vaccine developer Moderna signed a strategic cooperation contract with Shanghai authorities on Wednesday.
周三,美国信使核糖核酸疫苗开发商莫德纳与上海当局签署了一份战略合作合同。
One of the world's leading mRNA vaccine developers, Moderna focuses on cancer immunotherapy, mRNA-based medicine R&D and virus prevention technologies.
作为世界领先的mRNA疫苗开发商之一,Moderna专注于癌症免疫疗法、基于mRNA的药物研发和病毒预防技术。
Sanofi's vaccine manufacturing base in Shenzhen has realized localized production of flu vaccines and the Hangzhou manufacturing site is already an important facility in manufacturing solid preparations.
赛诺菲在深圳的疫苗生产基地已经实现了流感疫苗的本地化生产,杭州的生产基地已经是生产固体制剂的重要设施。
Two-dose bivalent vaccine for the human papilloma virus (HPV) becomes available in China, in an effort to better help women fight cervical cancer, according to British drugmaker GlaxoSmithKline.
英国制药商葛兰素史克(GlaxoSmithKline)表示,为了更好地帮助女性对抗宫颈癌症,中国将提供两剂二价人类乳头状瘤病毒疫苗。
Feng Bixia, the company's vice-president, said that Cervarix, the first HPV vaccine licensed for use in China, has extended its coverage to more than 280 Chinses cities since 2016, playing a vital role in protecting women from the threat of cervical cancer.
该公司副总裁冯碧霞表示,Cervarix是中国首款获准使用的HPV疫苗,自2016年以来,其覆盖范围已扩大到中国280多个城市,在保护女性免受癌症威胁方面发挥着至关重要的作用。
Going forward, the company will work with various stakeholders to accelerate vaccine innovation, enhance vaccine accessibility, lighten people's financial burden and put healthcare resources to more effective uses, she added.
她补充道,未来,该公司将与各利益相关者合作,加快疫苗创新,提高疫苗的可及性,减轻人们的经济负担,并使医疗资源得到更有效的利用。
"China has become one of the major growth drivers for our global vaccine business.
“中国已成为我们全球疫苗业务的主要增长动力之一。
The quadrivalent flu vaccine Vaxigrip was approved in China in February for pediatric indications.
四价流感疫苗Vaxigrip于2月在中国获批用于儿科适应症。
"I believe that the vaccine industry in China and worldwide is likely to ride a new wave of strong growth in the post-COVID-19 pandemic era," said Triomphe.
Triomphe表示:“我相信,在新冠肺炎疫情后的时代,中国和世界各地的疫苗行业可能会迎来新一波强劲增长。”。
China's vaccine market has great growth potential, he added, as the Chinese government has been continually raising public vaccination levels on the way to fulfill its Healthy China 2030 initiative.
他补充道,中国疫苗市场具有巨大的增长潜力,因为中国政府在实现其“健康中国2030”倡议的过程中不断提高公众疫苗接种水平。
"China's achievement in developing a robust public health system has been remarkable over the past years and vaccine use in the country has expanded largely.
“过去几年,中国在发展强大的公共卫生系统方面取得了显著成就,疫苗在中国的使用也大幅扩大。
"With local vaccine companies improving their technology, I believe the excellence in production, logistics and supply can further benefit the country in realizing high-quality development," Triomphe stated.
Triomphe表示:“随着当地疫苗公司提高技术,我相信在生产、物流和供应方面的卓越表现可以进一步有利于国家实现高质量发展。”。
Shenzhen is home to Sanofi's flu vaccine production plant built in 2007, the first and only foreign-owned vaccine production site in China.
深圳是赛诺菲流感疫苗生产厂的所在地,该厂建于2007年,是中国第一家也是唯一一家外资疫苗生产厂。
In 2021, the company inaugurated its Greater Bay Area International Vaccine Innovation Center in the city.
2021年,该公司在该市成立了大湾区国际疫苗创新中心。
When influenza vaccination rates among school-age children in Shenzhen participating in the study increased from 42 percent to 76 percent, the vaccine could be an effective measure to slash the financial burden of hospitalization by 107 million yuan ($15.53 million).
当参与这项研究的深圳学龄儿童的流感疫苗接种率从42%提高到76%时,该疫苗可能是一项有效措施,可以减少1.07亿元(1553万美元)的住院经济负担。
According to the agreement, the two sides will also leverage the Greater Bay Area International Vaccine Innovation Center, which was jointly established by the company and the Shenzhen government, as a platform to promote the innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
根据协议,双方还将利用公司与深圳市政府共同成立的大湾区国际疫苗创新中心,作为推动广东-香港-马考大湾区生物制药产业创新发展的平台。
Sanofi and the Shenzhen government had previously in 2019 signed a memorandum of understanding regarding a strategic cooperation in vaccine innovation.
赛诺菲和深圳政府此前于2019年签署了一份关于疫苗创新战略合作的谅解备忘录。
In 2021, the two parties established the GBA International Vaccine Innovation Center in Pingshan district.
2021年,双方在平山区成立了GBA国际疫苗创新中心。
Everest Medicines, a Hong Kong-listed Chinese biopharmaceutical company, announced the official opening of its messenger RNA vaccine industrialization base in Jiashan, Zhejiang province, on Tuesday.
周二,在香港上市的中国生物制药公司Everest Medicines宣布,其位于浙江嘉善的信使核糖核酸疫苗产业化基地正式启用。
The company has announced its formulation of a candidate COVID-19 vaccine, with clinical trials scheduled to kick off in China this year.
该公司宣布了其候选新冠肺炎疫苗的配方,临床试验计划于今年在中国启动。
The drop in January-November profits was mainly driven by declining profits in the steel and oil processing sectors and two key COVID-19 vaccine enterprises, NBS senior statistician Zhu Hong said in a statement accompanying the data.
国家统计局高级统计师朱红在数据附带的一份声明中表示,1月至11月利润下降的主要原因是钢铁和石油加工行业以及两家新冠肺炎疫苗关键企业的利润下降。
Sinopharm is the only enterprise in the world to have independently developed four COVID-19 vaccines via three technical platforms-two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是世界上唯一一家通过三个技术平台自主研发4种新冠肺炎疫苗的企业——两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗。
Sinopharm is the only enterprise in the world that has independently developed four COVID-19 vaccines via three technical platforms -- two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是全球唯一一家通过两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗三大技术平台自主研发四种新冠肺炎疫苗的企业。
Sinovac Biotech's COVID-19 vaccine called CoronaVac has been approved for children aged six months to three years in Hong Kong from Thursday, the Beijing-based biopharmaceutical product provider said on Wednesday.
总部位于北京的生物制药产品提供商科兴生物周三表示,该公司的新冠肺炎疫苗CoronaVac已于周四在香港获准用于6个月至3岁的儿童。
China's COVID-19 vaccine makers are expected to step up efforts to pursue innovation-driven high-quality development, based on their fast growth in the past few years, according to industry experts and business leaders.
行业专家和商界领袖表示,预计中国新冠肺炎疫苗制造商将在过去几年快速增长的基础上,加大力度,追求创新驱动的高质量发展。
Since the outbreak of the disease, Chinese vaccine developers have moved swiftly to design vaccines against the contagion.
自该疾病爆发以来,中国疫苗开发商迅速采取行动,设计出对抗传染病的疫苗。
The total number of COVID-19 vaccine doses administered on the Chinese mainland was around 3.41 billion as of July 14, data from the National Health Commission showed.
国家卫生健康委员会的数据显示,截至7月14日,中国大陆接种新冠肺炎疫苗的总剂量约为34.1亿剂。
However, analysts said domestic vaccine producers must face the reality of shrinking demand for COVID-19 vaccines, and refocus on product quality improvements while strengthening efforts to better meet disease prevention goals in both global and domestic markets.
然而,分析人士表示,国内疫苗生产商必须面对新冠肺炎疫苗需求萎缩的现实,在加强努力以更好地实现全球和国内市场的疾病预防目标的同时,重新关注产品质量改进。
A report from Southwest Securities said nearly 64 percent of the world's population has already been vaccinated with at least one dose of a COVID vaccine, while around 57 percent have been fully inoculated.
西南证券的一份报告称,全球近64%的人口已经接种了至少一剂新冠疫苗,而约57%的人已经完全接种。
Chen Jia, a researcher at the International Monetary Institute of the Renmin University of China, said:"Chinese vaccine companies have become more aware of the importance of independent innovation.
中国人民大学国际货币研究所研究员陈佳说:“中国疫苗公司越来越意识到自主创新的重要性。
Sinovac, which has been granted access licenses by more than 60 countries, international organizations and regions in total for its COVID-19 vaccine CoronaVac, has supplied more than 2.8 billion doses worldwide.
科兴公司新冠肺炎疫苗CoronaVac已获得60多个国家、国际组织和地区的准入许可,该公司已在全球供应超过28亿剂疫苗。
The company has strengthened its capability in industrial chain coordination and global cooperation regarding key links for vaccine design and supply, such as animal testing, clinical trials, product registration and production.
该公司加强了在动物试验、临床试验、产品注册和生产等疫苗设计和供应关键环节的产业链协调和全球合作能力。
Sinopharm, parent company of CNBG, currently produces nearly 100 vaccine products and more than 200 bio-products.
中国生物天然气集团的母公司国药集团目前生产近100种疫苗产品和200多种生物产品。
Chen, with RUC, said Chinese vaccine makers' deeper participation in global vaccine industrial chains has created favorable conditions for them to increase their presence in global markets.
中国人民大学的陈表示,中国疫苗制造商对全球疫苗产业链的深入参与为他们增加在全球市场的影响力创造了有利条件。
The improvement of Chinese vaccine enterprises' position in the global vaccine industry was achieved in the past two years through expanding production capacity, establishing cross-region logistics, improving commercialization, and strengthening international cooperation, he said.
他说,中国疫苗企业在全球疫苗行业地位的提高是在过去两年中通过扩大产能、建立跨地区物流、提高商业化水平和加强国际合作实现的。
Such experience is especially valuable for Chinese vaccine makers as they are expected to strengthen independent research for in-house innovations in pursuit of stronger competitiveness in both domestic and global markets, he said.
他说,这些经验对中国疫苗制造商来说尤其有价值,因为他们有望加强对内部创新的独立研究,以追求在国内和全球市场上更强的竞争力。
Unlike views of the desolate desert surroundings, indoors there are many experts busy arranging the interior layout of the vaccine production equipment and power lines-all for the purpose of better arming the region in its future fight against the COVID-19 pandemic.
与荒凉的沙漠环境不同,室内有许多专家正忙于安排疫苗生产设备和电力线的内部布局,所有这些都是为了更好地武装该地区未来抗击新冠肺炎疫情。
After completion, the very first vaccine production line with direct involvement of China in the UAE will play a key role in delivering COVID-19 vaccines in the Middle East and North Africa, with its annual capacity reaching 200 million doses per year, said its builder-the China State Construction Engineering Corp Middle East.
阿联酋第一条由中国直接参与的疫苗生产线建成后,将在中东和北非提供新冠肺炎疫苗方面发挥关键作用,其年产能将达到每年2亿剂。
Also serving as the deputy general manager of CSCEC Middle East's Building Division, Zheng said that though work only began about a year ago, the construction team is on track to deliver the vaccine factory at record speed with completion expected in the coming months.
同时担任中建中东建筑部副总经理的郑表示,尽管工程大约一年前才开始,但施工团队正在以创纪录的速度交付疫苗工厂,预计在未来几个月内完工。
Last year, an agreement was reached for vaccines by China National Pharmaceutical Group Co Ltd, or Sinopharm, to be produced in the region through a partnership between China National Biotec Group Co, a Sinopharm unit, and UAE-owned firm G42-the same firms also responsible for the vaccine factory.
去年,中国国药集团有限公司(Sinopharm)通过国药集团旗下的中国生物技术集团公司(China National Biotec Group Co)和UAE旗下的G42公司(同样负责疫苗工厂)之间的合作,达成了在该地区生产疫苗的协议。
Apart from the UAE facility, China is also cooperating with Serbia in building a vaccine production facility, labeling the country the first one in Europe to produce vaccines by Sinopharm.
除了阿联酋的设施,中国还与塞尔维亚合作建设疫苗生产设施,使该国成为欧洲第一个由国药集团生产疫苗的国家。
According to a report in the People's Daily, till June, China has provided more than 2.2 billion doses of COVID-19 vaccines to more than 120 countries and international organizations, and has successively transferred vaccine-related technology to, or cooperated in vaccine production with, more than 20 countries, forming an overseas annual production capacity of 1 billion doses.
据《人民日报》报道,截至6月,中国已向120多个国家和国际组织提供超过22亿剂新冠肺炎疫苗,并先后向20多个国家转让或合作疫苗相关技术,形成了10亿剂的海外年生产能力。
China's overseas vaccine production facilities, as part of the second-largest economy's caring moves in ways of infrastructure and healthcare, are playing a major role in helping "narrow the COVID-19 prevention gap between nations", said Deng Boqing, vice-chairman of the China International Development Cooperation Agency during the 2022 annual meeting of the Boao Forum in Hainan province in April.
邓伯清表示,作为第二大经济体在基础设施和医疗保健方面的关爱行动的一部分,中国的海外疫苗生产设施在帮助“缩小国家间新冠肺炎预防差距”方面发挥着重要作用,4月,在海南省举行的博鳌论坛2022年年会上,中国国际开发合作署副主席。
Sinovac Biotech Ltd, a biopharmaceutical product provider in China, officially unveiled a vaccine quality research center in Changping district of Beijing on Sunday.
周日,中国生物制药产品供应商科兴生物技术有限公司在北京昌平区正式启用了一个疫苗质量研究中心。
Two of its vaccine products have earned the prequalification certification from the World Health Organization, which means the WHO recognizes the quality, safety and efficacy of the products, while its COVID-19 vaccine has been approved by the organization for emergency use.
其两种疫苗产品获得了世界卫生组织的资格预审认证,这意味着世界卫生组织认可这些产品的质量、安全性和有效性,而其新冠肺炎疫苗已获得该组织的紧急使用批准。
Sinovac Biotech Ltd, a biopharmaceutical product provider in China, announced on Tuesday that a phase-3 clinical trial for its inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile.
中国生物制药产品供应商科兴生物技术有限公司周二宣布,其四价流感灭活疫苗的三期临床试验已在智利共和国启动。
The clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3-year-old and above.
该临床试验旨在评估四价流感疫苗在3岁及以上人群中的免疫原性和安全性。
Half of them will receive one or two doses of the Sinovac vaccine, while the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
其中一半将接种一剂或两剂科兴疫苗,另一半将接种在智利上市的不同四价流感疫苗。
All of the participants will be observed for 28 days following the completed inoculation to evaluate the vaccine safety.
所有参与者将在完成接种后接受28天的观察,以评估疫苗的安全性。
The study results are expected to provide further scientific evidence on the efficacy and safety of the company’s quadrivalent influenza vaccine to promote its worldwide use, Sinovac said.
科兴表示,该研究结果有望为该公司四价流感疫苗的有效性和安全性提供进一步的科学证据,以促进其在全球范围内的使用。
The quadrivalent influenza vaccine has been approved in China since June 2020. liuzhihua@chinadaily.
四价流感疫苗已于2020年6月在中国获批。liuzhihua@chinadaily.
Chinese vaccine producer Sinovac Biotech officially kicked off a clinical trial in Hong Kong on Monday to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine which will be used as a booster shot in healthy adults.
中国疫苗生产商科兴生物周一在香港正式启动临床试验,以评估其奥密克戎特异性新冠肺炎灭活疫苗的安全性和免疫原性,该疫苗将用于健康成年人的加强针。
The trial program plans to recruit around 300 or more healthy volunteers who are above the age of 18 and who have already been inoculated with two or three shots of either inactivated or mRNA COVID-19 vaccine.
该试验计划招募约300名或更多18岁以上的健康志愿者,他们已经接种了两针或三针新冠肺炎灭活疫苗或mRNA疫苗。
Sinovac obtained a sample of the Omicron variant in early December last year to further the research and development of its Omicron-specific inactivated COVID-19 vaccine.
去年12月初,科兴获得了奥密克戎变异株的样本,以进一步研发其奥密克龙特异性新冠肺炎灭活疫苗。
Preclinical studies have showed the vaccine is safe and effective on animals, the company said.
该公司表示,临床前研究表明,该疫苗对动物安全有效。
These employees have received vaccine booster shots and will be dedicated to sorting and last-mile delivery jobs as soon as arriving in Shanghai, the company said.
该公司表示,这些员工已经接种了疫苗加强针,一旦抵达上海,他们将致力于分拣和最后一英里的配送工作。
Through this proposed partnership with CR Pharma, the mRNA-focused company will be well-positioned to advance its potentially best-in-class mRNA vaccine candidates through Chinese regulatory pathways and into commercialization, Everest said.
Everest表示,通过与CR Pharma的拟议合作,这家专注于信使核糖核酸的公司将处于有利地位,能够通过中国的监管途径推进其潜在的同类最佳信使核糖核酸候选疫苗并实现商业化。
CR Pharma, a subsidiary of State-owned China Resources (Holdings) Co Ltd, said through this cooperation, the two companies intend to work together in the development of mRNA COVID-19 vaccine and the development of other potential products using the mRNA technology platform, to contribute to China's public health.
国有华润(控股)有限公司的子公司华润医药表示,通过此次合作,两家公司打算共同开发mRNA新冠肺炎疫苗,并利用mRNA技术平台开发其他潜在产品,为中国的公共健康做出贡献。
The mRNA company will accelerate the late-stage development and registration of its potentially best-in-class mRNA COVID-19 vaccine candidate, PTX-COVID19-B, and continue the development of a second-generation COVID-19 vaccine with broad spectrum activity designed to be effective against but not limited to the Omicron variants, as well as two Collaboration Project with Providence that target new mRNA based vaccines, Everest said.
mRNA公司将加快其潜在的最佳mRNA新冠肺炎候选疫苗PTX-COVID19-B的后期开发和注册,并继续开发具有广谱活性的第二代新冠肺炎疫苗,该疫苗旨在有效对抗但不限于奥密克戎变异株,以及与普罗维登斯的两个针对新型信使核糖核酸疫苗的合作项目,Everest说。
Animal Health posted strong double-digit growth and continued to be the leader in swine vaccine and pet antiparasitics segments.
动物健康公司实现了两位数的强劲增长,并继续成为猪疫苗和宠物抗寄生虫领域的领导者。
According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.
据Reed介绍,赛诺菲已将多种潜在的变革性疗法优先用于患者需求未得到高度满足的领域,包括世界上第一种被批准用于治疗中重度特应性皮炎的靶向生物制剂Dupixent,用于治疗血友病的Fitusiran和Efanesoctocog alfa(BIVV001),用于治疗炎症性疾病的Amlitelimab,Amcenestant治疗乳腺癌症,RSV疫苗Nirsevimab和Tolebrutinib治疗多发性硬化症。
We've already begun the process to align our global systems, processes, and capabilities to offer world-class solutions to customers working on all bioproduction platforms, including monoclonal antibodies, cell and gene therapies, and mRNA, and supports both therapy and vaccine manufacturing including COVID-19 in China," Wang added.
王补充道:“我们已经开始调整我们的全球系统、流程和能力,为在所有生物生产平台上工作的客户提供世界级的解决方案,包括单克隆抗体、细胞和基因疗法以及mRNA,并支持治疗和疫苗生产,包括中国的新冠肺炎。”。
Narayana Rao Rapolu, vice-president of Avantor's biopharma business in Asia, Middle East, and Africa, said that China is a major COVID-19 vaccine supplier, and that the company has throughout the pandemic supported its customers in improving the speed of emergency response through a range of products related to COVID-19 detection, safety and treatment.
Avantor在亚洲、中东和非洲的生物制药业务副总裁Narayana Rao Rapolu表示,中国是新冠肺炎疫苗的主要供应商,该公司在整个疫情期间通过一系列与新冠肺炎检测、安全和治疗相关的产品,支持客户提高应急响应速度。
"We have worked closely with COVID-19 vaccine and therapy developers in China and prioritized supplies of mission-critical process chemicals, raw materials and single use consumables going into research and development as well as manufacturing to enable the faster development and supply of COVID-19 vaccines and therapies to patients in China and globally," Rapolu said.
拉波卢说:“我们与中国的新冠肺炎疫苗和疗法开发商密切合作,优先供应用于研发和制造的关键任务工艺化学品、原材料和一次性消耗品,以加快新冠肺炎疫苗和疗法的开发和供应,造福中国和全球患者。”。
It added that it has accelerated its review of COVID-19-related patent applications, offering a quick channel for those related to vaccine development and epidemic control.
它补充说,它已经加快了对新冠肺炎相关专利申请的审查,为疫苗开发和疫情控制相关的专利申请提供了一个快速渠道。
State drugmaker provided more than 2.5b doses to 112 regions, world bodiesThe world's first COVID-19 vaccine developed by State-owned drugmaker Sinopharm marked the first anniversary of its registration and its launch in the market on Thursday.
国有制药商向112个地区和世界机构提供了超过25亿剂疫苗。由国有制药商国药集团开发的全球首款新冠肺炎疫苗于周四庆祝其注册并上市一周年。
Back in June 2020, China and the United Arab Emirates started to conduct phase 3 clinical trials of an inactivated COVID-19 vaccine in the UAE.
早在2020年6月,中国和阿拉伯联合酋长国就开始在阿联酋进行新冠肺炎灭活疫苗的3期临床试验。
It was also the first time that China sent a team of nearly 100 experts to conduct vaccine research overseas.
这也是中国首次派出近百名专家团队赴海外进行疫苗研究。
With a half year's efforts and help from some 63,000 volunteers, the two countries conducted sufficient joint experiments, and the first vaccine was finally debuted and registered in the UAE in December last year.
经过半年的努力和约6.3万名志愿者的帮助,两国进行了充分的联合实验,第一种疫苗终于于去年12月在阿联酋首次亮相并注册。
Later on, Sinopharm's COVID-19 vaccine was registered and debuted in 10 countries, including Bahrain, Bolivia, Seychelles, Thailand, Malaysia, Morocco and Peru.
随后,国药集团新冠肺炎疫苗在巴林、玻利维亚、塞舌尔、泰国、马来西亚、摩洛哥和秘鲁等10个国家注册并首次亮相。
So far, the vaccine has been approved for emergency use or market access in 112 countries, regions and international organizations.
到目前为止,该疫苗已在112个国家、地区和国际组织获准紧急使用或进入市场。
"In March this year, China and the UAE launched Sinopharm's vaccine production line in the UAE.
“今年3月,中国和阿联酋启动了国药集团在阿联酋的疫苗生产线。
"The vaccine has played an important role in helping the UAE fight the pandemic and daily new cases of COVID-19 in the UAE have dropped to about 50.
“该疫苗在帮助阿联酋抗击疫情方面发挥了重要作用,阿联酋每日新增新冠肺炎病例已降至约50例。
Sinopharm's COVID-19 vaccine has become the one that has been approved in the most countries, and most widely accepted for vaccinations worldwide.
国药集团的新冠肺炎疫苗已成为在大多数国家获得批准的疫苗,也是全球最广泛接受的疫苗。
The company has built six production plants and three labs in China, and the annual vaccine production capacity has exceeded 7 billion doses.
该公司在中国建立了六个生产工厂和三个实验室,年疫苗生产能力已超过70亿剂。
Sinopharm has also cooperated with Serbia, Morocco, Bangladesh and Hungary for COVID-19 vaccine packaging overseas.
国药集团还与塞尔维亚、摩洛哥、孟加拉国和匈牙利合作,在海外包装新冠肺炎疫苗。
In the United Arab Emirates, our vaccine production facility has been completed.
在阿拉伯联合酋长国,我们的疫苗生产设施已经完工。
In Morocco and Serbia, we are building new vaccine production facilities.
在摩洛哥和塞尔维亚,我们正在建设新的疫苗生产设施。
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond COVID-19.
该协议标志着百度利用其在计算生物学方面的优势,在新冠肺炎之后的现实世界制药实践中优化mRNA疫苗和治疗设计,这是一个里程碑。
"The emerging mRNA technology has rapidly advanced the science of vaccine and drug development for infectious diseases like COVID-19," said Wu Tian, corporatexa0vice-president of Baidu.
“新兴的mRNA技术迅速推动了新冠肺炎等传染病疫苗和药物开发的科学发展,”百度公司副总裁吴天表示。
"While mRNA has proved to be an innovative technology for vaccine development, instability remains a major limitation that affects the storage, distribution and efficacy of mRNA vaccines.
“尽管信使核糖核酸已被证明是一种创新的疫苗开发技术,但不稳定性仍然是影响信使核糖核酸疫苗储存、分发和疗效的主要限制因素。
DXY announced in November last year it had teamed up with major vaccine enterprises, such as MSD, GSK, Sinovac Biotech and Hualan Biological Engineering, to establish a vaccination service platform.
丁香园去年11月宣布,已与默沙东、葛兰素史克、科兴生物和华兰生物工程等主要疫苗企业合作,建立疫苗接种服务平台。
考试真题例句(机器翻译仅供参考)
全部
高考
考研
四级

高考Measles, which once killed 450 children each year and disabled even more, was nearly wiped out in the united states 14 years ago by the universal use of the MMR vaccine.

麻疹曾一度每年导致450名儿童死亡,甚至更多儿童致残。14年前,由于MMR疫苗的普遍使用,麻疹在美国几乎被消灭。

2017年高考英语北京卷 阅读理解 阅读C 原文

考研The new vaccine, which is different from the annual flu vaccine, is available ahead of expectations.

新疫苗不同于年度流感疫苗,提前上市。

2010年考研真题(英语二)完形填空 Section Ⅰ

高考Seventeen states allow parents to get an exemption豁免, sometimes just by signing a paper saying they personally object to a vaccine.

17个州允许父母获得豁免豁免, 有时只是签署一份文件说他们个人反对疫苗。

2017年高考英语北京卷 阅读理解 阅读C 原文

高考This is called "herd immunity", which protects the people who get hurt easily, including those who can't be vaccinated for medical reasons, babies too young to get vaccinated and people on whom the vaccine doesn't work.

这就是所谓的“群体免疫”,它保护那些容易受伤的人,包括那些因为医疗原因不能接种疫苗的人,那些太小而不能接种疫苗的婴儿,以及那些疫苗不起作用的人。

2017年高考英语北京卷 阅读理解 阅读C 原文

高考The resistance to vaccine has continued for decades, and it is driven by a real but very small risk.

对疫苗的耐药性已经持续了几十年,这是由一个真实但非常小的风险驱动的。

2017年高考英语北京卷 阅读理解 阅读C 原文

考研Federal health officials released Tamiflu for children from the national stockpile and began taking orders from the states for the new swine flu vaccine.

联邦卫生官员从国家储备中为儿童发放了达菲,并开始接受各州关于新型猪流感疫苗的订单。

2010年考研真题(英语二)完形填空 Section Ⅰ

四级More than 200 viruses can cause cold symptoms, while the flu is caused by three viruses—flu A, B and C. There is no cure for either illness, but the flu can be prevented by the flu vaccine (疫苗), which is, for most people, the best way to fight the flu, according to the ALA.

200多种病毒会引起感冒症状,而流感是由三种病毒引起的——甲型、乙型和丙型流感。这两种疾病都无法治愈,但流感疫苗可以预防(疫苗), 根据ALA的说法,对大多数人来说,这是对抗流感的最佳方法。

2005年1月大学英语四级(CET-4)真题

四级There is, of course, no vaccine for the common cold.

当然,目前还没有针对普通感冒的疫苗。

2005年1月大学英语四级(CET-4)真题

========================================================
部分内容来自网络,如有版权问题请与我们联系
未经许可,严禁转发。QQ交流群:688169419
========================================================
0
0